# US 2025/0049857 A1 · Compositions and methods for treating kidney disease and other disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049857 A1
- Document ID: US20250049857A1
- Status: Published application
- Kind: A1
- Application number: 18/889,664
- Filed: 2024-09-19
- Published: 2025-02-13
- Earliest claimed: 2023-06-01
- Assignees: Livekidney.Bio Ltd
- Applicants: Livekidney.Bio Ltd
- Inventors: MASHA SIMANOVSKY; SHIMON AMSELEM; ALON YAAR
- Web page: https://patentgrep.com/patent/US20250049857A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- C12N 5/0653: {Adipocytes; Adipose tissue}
- C12N 5/0686: {Kidney cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods for treatment of kidney disease, comprising administering to a patient in need thereof a cell-derived product to the perirenal adipose tissue (PRAT) of the patient. Optionally, the cell derived product is a plurality of mesenchymal stromal cells. Other diseases may be treated using this method including: a disease of the liver, cardiovascular disease, inflammatory disease, fibrotic disease, autoimmune disease, and disease of a visceral organ.

## Claims

### Claim 1

A method for treatment of a subject suffering from kidney disease comprising administering to the perirenal adipose tissue of the subject a cellular product in an amount effective to show an improvement in a symptom or marker of kidney disease in the subject.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the cellular product comprises a plurality of mesenchymal stromal cells (MSC).

### Claim 3 (depends on 2)

The method according to claim 2 wherein the MSC is of umbilical cord origin.

### Claim 4 (depends on 2)

The method according to claim 2 wherein the cellular product comprises an extracellular vesicle or an exosome.

### Claim 5 (depends on 4)

The method according to claim 4 wherein the extracellular vesicle or exosome comprises an active ingredient selected from the group consisting of a sodium-glucose cotransporter-2 (SGLT2) inhibitor, angiotensin receptor blocker (ARB), angiotensin-converting-enzyme (ACE) inhibitor, and a mineralocorticoid receptor antagonist.

### Claim 6 (depends on 2)

The method according to claim 2 wherein the amount of MSC administered is between 10-100 million cells per ml.

### Claim 7

The method according to 1 wherein the amount of MSC administered is up to 500 million cells per administration.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the subject suffers from a disease selected from the group consisting of: chronic kidney disease, end stage kidney disease, Fabry disease, cystinosis, glomerulonephritis, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, atypical hemolytic uremic syndrome, kidney fibrosis, nephrogenic systemic fibrosis, Focal Segmental Glomerulosclerosis (FSGS), APOLI Nephropathy, and polycystic kidney disease.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the subject suffers from a kidney disease co-morbidity selected from the group consisting of: high blood pressure, diabetes, and obesity.
